Comments
Loading...

Encompass Health Analyst Ratings

EHCNYSE
Logo brought to you by Benzinga Data
Consensus Rating1
Overweight
Highest Price Target1
$135.00
Lowest Price Target1
$57.00
Consensus Price Target1
$99.89

Encompass Health Analyst Ratings and Price Targets | NYSE:EHC | Benzinga

Encompass Health Corp has a consensus price target of $99.89 based on the ratings of 18 analysts. The high is $135 issued by Stephens & Co. on June 5, 2025. The low is $57 issued by Barclays on March 14, 2023. The 3 most-recent analyst ratings were released by Stephens & Co., Keybanc, and UBS on June 5, 2025, May 27, 2025, and April 28, 2025, respectively. With an average price target of $133.33 between Stephens & Co., Keybanc, and UBS, there's an implied 11.49% upside for Encompass Health Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
3
Feb
5
Apr
1
May
1
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Stephens & Co.
Keybanc
UBS
RBC Capital
Truist Securities

1calculated from analyst ratings

Analyst Ratings for Encompass Health

Buy NowGet Alert
06/05/2025Buy Now12.89%Stephens & Co.
Raj Kumar
$135 → $135ReiteratesOverweight → OverweightGet Alert
05/27/2025Buy Now12.89%Keybanc
Paul Knight
$122 → $135MaintainsOverweightGet Alert
04/28/2025Buy Now8.7%UBS
Andrew Mok
$117 → $130MaintainsBuyGet Alert
04/28/2025Buy Now4.52%RBC Capital
Ben Hendrix
$110 → $125MaintainsOutperformGet Alert
04/28/2025Buy Now12.89%Truist Securities
David Macdonald
$116 → $135ReiteratesBuy → BuyGet Alert
04/25/2025Buy Now2.02%Keybanc
Matthew Gillmor
$120 → $122MaintainsOverweightGet Alert
04/25/2025Buy Now7.87%Barclays
Andrew Mok
$118 → $129MaintainsOverweightGet Alert
02/11/2025Buy Now-8.02%RBC Capital
Ben Hendrix
$110 → $110ReiteratesOutperform → OutperformGet Alert
02/10/2025Buy Now0.34%Keybanc
Matthew Gillmor
$117 → $120MaintainsOverweightGet Alert
02/07/2025Buy Now-1.33%Barclays
Andrew Mok
$116 → $118MaintainsOverweightGet Alert
10/30/2024Buy Now-8.02%RBC Capital
Ben Hendrix
$105 → $110MaintainsOutperformGet Alert
10/30/2024Buy Now-3%Truist Securities
David Macdonald
$108 → $116ReiteratesBuy → BuyGet Alert
10/29/2024Buy Now-3%Barclays
Andrew Mok
$109 → $116MaintainsOverweightGet Alert
10/29/2024Buy Now-2.17%Keybanc
Matthew Gillmor
$115 → $117MaintainsOverweightGet Alert
10/14/2024Buy Now-9.69%Truist Securities
David Macdonald
$104 → $108MaintainsBuyGet Alert
10/11/2024Buy Now-3.84%Keybanc
Matthew Gillmor
→ $115Initiates → OverweightGet Alert
09/26/2024Buy Now-12.2%RBC Capital
Ben Hendrix
$95 → $105MaintainsOutperformGet Alert
09/25/2024Buy Now-8.02%UBS
Andrew Mok
$100 → $110MaintainsBuyGet Alert
08/15/2024Buy Now-13.04%Truist Securities
David Macdonald
$100 → $104MaintainsBuyGet Alert
08/08/2024Buy Now-16.38%UBS
Andrew Mok
$96 → $100MaintainsBuyGet Alert
08/06/2024Buy Now-12.2%Stephens & Co.
Scott Fidel
$105 → $105ReiteratesOverweight → OverweightGet Alert
08/06/2024Buy Now-8.86%Barclays
Andrew Mok
$113 → $109MaintainsOverweightGet Alert
07/15/2024Buy Now-16.38%Truist Securities
David Macdonald
$95 → $100MaintainsBuyGet Alert
07/10/2024Buy Now-5.51%Barclays
Andrew Mok
$108 → $113MaintainsOverweightGet Alert
07/10/2024Buy Now-16.38%Leerink Partners
Whit Mayo
→ $100Initiates → OutperformGet Alert
06/05/2024Buy Now-21.4%Stephens & Co.
Scott Fidel
$94 → $94ReiteratesOverweight → OverweightGet Alert
05/22/2024Buy Now-20.56%RBC Capital
Ben Hendrix
$83 → $95MaintainsOutperformGet Alert
04/26/2024Buy Now-20.56%Raymond James
John Ransom
$85 → $95ReiteratesStrong Buy → Strong BuyGet Alert
04/25/2024Buy Now-9.69%Barclays
Andrew Mok
$101 → $108MaintainsOverweightGet Alert
04/25/2024Buy Now-20.56%Mizuho
Ann Hynes
$93 → $95MaintainsBuyGet Alert
03/28/2024Buy Now-15.54%Barclays
Andrew Mok
$95 → $101MaintainsOverweightGet Alert
03/06/2024Buy Now-20.56%Barclays
Andrew Mok
→ $95Initiates → OverweightGet Alert
02/09/2024Buy Now-30.6%RBC Capital
Ben Hendrix
$83 → $83ReiteratesOutperform → OutperformGet Alert
02/09/2024Buy Now-28.09%Truist Securities
David Macdonald
$82 → $86MaintainsBuyGet Alert
02/09/2024Buy Now-31.43%Mizuho
Ann Hynes
$77 → $82MaintainsBuyGet Alert
01/16/2024Buy Now-28.92%Stephens & Co.
Scott Fidel
$85 → $85ReiteratesOverweight → OverweightGet Alert
09/28/2023Buy Now-30.6%RBC Capital
Ben Hendrix
→ $83ReiteratesOutperform → OutperformGet Alert
08/08/2023Buy Now-30.6%RBC Capital
Ben Hendrix
$70 → $83MaintainsOutperformGet Alert
08/04/2023Buy Now-41.47%Barclays
Jason Goldberg
$61 → $70MaintainsEqual-WeightGet Alert
08/04/2023Buy Now-33.1%Credit Suisse
Jonathan Yong
$76 → $80MaintainsOutperformGet Alert
08/03/2023Buy Now-28.92%Raymond James
John Ransom
$80 → $85MaintainsStrong BuyGet Alert
08/03/2023Buy Now-31.43%Truist Securities
David Macdonald
$75 → $82MaintainsBuyGet Alert
08/03/2023Buy Now-35.61%Mizuho
Ann Hynes
$74 → $77MaintainsBuyGet Alert
08/03/2023Buy Now-40.63%Barclays
Jason Goldberg
$61 → $71MaintainsEqual-WeightGet Alert
07/20/2023Buy Now-34.78%Stephens & Co.
Scott Fidel
→ $78ReiteratesOverweight → OverweightGet Alert
06/29/2023Buy Now-34.78%Stephens & Co.
Scott Fidel
$74 → $78MaintainsOverweightGet Alert
05/02/2023Buy Now-41.47%RBC Capital
Ben Hendrix
$66 → $70MaintainsOutperformGet Alert
05/02/2023Buy Now-33.1%Raymond James
John Ransom
$72 → $80MaintainsStrong BuyGet Alert
05/01/2023Buy Now-38.96%Deutsche Bank
Pito Chickering
$70 → $73MaintainsBuyGet Alert
05/01/2023Buy Now-38.12%Stephens & Co.
Scott Fidel
$70 → $74MaintainsOverweightGet Alert
05/01/2023Buy Now-36.45%Credit Suisse
Jonathan Yong
$73 → $76MaintainsOutperformGet Alert
05/01/2023Buy Now-38.12%Mizuho
Ann Hynes
$69 → $74MaintainsBuyGet Alert
04/28/2023Buy Now-38.12%B of A Securities
Kevin Fischbeck
$69 → $74MaintainsBuyGet Alert
04/04/2023Buy Now-48.99%Barclays
Jason Goldberg
$57 → $61MaintainsEqual-WeightGet Alert
03/14/2023Buy Now-52.34%Barclays
Steve Valiquette
→ $57Initiates → Equal-WeightGet Alert
02/09/2023Buy Now-37.29%Truist Securities
David Macdonald
$70 → $75MaintainsBuyGet Alert
02/09/2023Buy Now-38.96%Credit Suisse
A.J. Rice
$62 → $73MaintainsOutperformGet Alert
02/09/2023Buy Now-42.3%Mizuho
Ann Hynes
$65 → $69MaintainsBuyGet Alert
02/08/2023Buy Now-41.47%Stephens & Co.
Scott Fidel
→ $70MaintainsOverweightGet Alert
10/28/2022Buy Now-51.5%Stephens & Co.
Scott Fidel
$60 → $58MaintainsOverweightGet Alert
10/28/2022Buy Now-39.79%Raymond James
John Ransom
$65 → $72MaintainsStrong BuyGet Alert
09/21/2022Buy Now-48.16%Credit Suisse
A.J. Rice
$63 → $62MaintainsOutperformGet Alert
08/24/2022Buy Now-44.81%RBC Capital
Ben Hendrix
$82 → $66MaintainsOutperformGet Alert
08/08/2022Buy Now-45.65%Truist Securities
David Macdonald
$75 → $65MaintainsBuyGet Alert
08/04/2022Buy Now-45.65%BMO Capital
Matt Borsch
$83 → $65MaintainsOutperformGet Alert
08/04/2022Buy Now-45.65%Raymond James
John Ransom
$70 → $65MaintainsStrong BuyGet Alert
08/04/2022Buy Now-47.32%Barclays
Steve Valiquette
$80 → $63MaintainsOverweightGet Alert

FAQ

Q

What is the target price for Encompass Health (EHC) stock?

A

The latest price target for Encompass Health (NYSE:EHC) was reported by Stephens & Co. on June 5, 2025. The analyst firm set a price target for $135.00 expecting EHC to rise to within 12 months (a possible 12.89% upside). 23 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Encompass Health (EHC)?

A

The latest analyst rating for Encompass Health (NYSE:EHC) was provided by Stephens & Co., and Encompass Health reiterated their overweight rating.

Q

When was the last upgrade for Encompass Health (EHC)?

A

There is no last upgrade for Encompass Health

Q

When was the last downgrade for Encompass Health (EHC)?

A

There is no last downgrade for Encompass Health.

Q

When is the next analyst rating going to be posted or updated for Encompass Health (EHC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Encompass Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Encompass Health was filed on June 5, 2025 so you should expect the next rating to be made available sometime around June 5, 2026.

Q

Is the Analyst Rating Encompass Health (EHC) correct?

A

While ratings are subjective and will change, the latest Encompass Health (EHC) rating was a reiterated with a price target of $135.00 to $135.00. The current price Encompass Health (EHC) is trading at is $119.59, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch